Clinical Trial Update: Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

A Phase 2 trial update announcing ongoing recruitment for neoadjuvant chemo-immunotherapy in stage III PD-L1 positive non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Fondazione Ricerca Traslazionale | Conditions: Stage III NSCLC | Phase 2 | Status: RECRUITING